10-Q: Hestia Insight Shifts to AI, Reports Q3 Loss Amid Vending Exit

Hestia Insight Inc. reported a significant net loss for the nine months ended August 31, 2025, as it divests from vending operations to focus on AI product development and IP-based consulting, while also facing going concern doubts.

Summary

• Hestia Insight Inc. reported a net loss of $934,426 for the nine months ended August 31, 2025, a significant decline from a net income of $713,103 in the prior year period.
• Revenue plummeted to $8,000 for the nine months ended August 31, 2025, compared to $1,312,930 in the same period last year.
• The company has discontinued its legacy Healthy Vending Services and Portable Charging Network Business, completing the sale and termination of vending machine operations during the quarter ended August 31, 2025.
• A strategic shift is underway to focus on high-growth areas in AI product development and IP-based consulting.
• The Board approved a capital raise of up to $5 million through equity and/or convertible debt to fund AI expansion, R&D acceleration, marketing of AI consulting tools, and general corporate purposes.
• Total assets decreased significantly to $388,709 as of August 31, 2025, from $1,146,635 as of November 30, 2024, primarily due to a decrease in investments in equities and disposal of fixed assets.
• Total liabilities increased to $262,805 as of August 31, 2025, from $206,306 as of November 30, 2024, driven by an increase in related party notes payable.
• Accumulated deficits grew to $(1,048,748) as of August 31, 2025, from $(114,323) as of November 30, 2024.
• Cash and cash equivalents remained low at $39,956 as of August 31, 2025.
• Management expressed substantial doubt about the company's ability to continue as a going concern.

Sentiment

Score: 2

Explanation: The company faces severe financial distress with a significant net loss, drastically reduced revenue, and a 'going concern' warning. While the strategic pivot to AI and planned capital raise offer a glimmer of future potential, the current financial state and ineffective controls present substantial immediate challenges and risks.

Positives

• Strategic shift towards high-growth AI product development and IP-based consulting.
• Board approval for a capital raise of up to $5 million to support new strategic initiatives.
• Cash used in operating activities decreased to $(105,465) for the nine months ended August 31, 2025, from $(118,813) in the prior year, indicating a slight improvement in operational cash burn.

Negatives

• Significant net loss of $934,426 for the nine months ended August 31, 2025, compared to a net income of $713,103 in the prior year.
• Revenue declined drastically to $8,000 from $1,312,930 year-over-year.
• Substantial doubt about the company's ability to continue as a going concern due to insufficient revenues and dependence on external financing.
• Total assets decreased by over 66% from November 30, 2024, to August 31, 2025.
• Accumulated deficits increased significantly to over $1 million.
• Unrealized losses on equity investments increased to $(711,921) from $(409,653) year-over-year.
• Disclosure controls and procedures were deemed ineffective due to limited resources and employees.
• An approximately $64,000 receivable from Aqua Medical has not been recorded due to liquidity concerns and uncertainty of collection.

Risks

• Inability to raise additional equity capital or successfully develop and commercialize investments and services, which could prevent the company from achieving profitable operations and continuing as a going concern.
• Dependence on debt and equity financing to fund operations due to not yet establishing an ongoing source of revenues sufficient to cover operating costs.
• Uncertainty regarding the successful signing, closing, or implementation of definitive agreements for potential acquisitions and strategic partnerships in new areas of focus.
• Lack of patent protection for intellectual property, creating a risk of inability to adequately protect intellectual property rights.
• Competition from numerous advisory firms, technology vendors, and other organizations in the consulting business, and direct service providers, emerging technologies, and medical communication platforms as the business expands.
• High regulation and rapid changes in the U.S. healthcare industry, which could create unexpected liabilities, additional costs, or restrict operations.
• Ineffective disclosure controls and procedures due to limited resources and employees, potentially affecting the reliability and timeliness of financial reporting.
• Potential for significant costs associated with public company reporting requirements and corporate governance, including Sarbanes-Oxley Act compliance.
• The trading price of common stock and a downturn in the U.S. equity and debt markets could make it more difficult to obtain financing.
• Issuance of additional equity or debt securities could lead to stockholder dilution or new securities having senior rights.
• Inability to obtain additional capital could restrict growth and lead to cessation of operations.

Future Outlook

The company is undergoing a strategic shift, discontinuing legacy vending operations to focus on high-growth areas in AI product development and IP-based consulting. It intends to pursue acquisitions, licensing, or joint ventures in healthcare and biotech technologies. A capital raise of up to $5 million is planned to support this expansion, R&D, and marketing. However, the company acknowledges substantial doubt about its ability to continue as a going concern and will need to raise significant additional capital to fund operations and meet obligations.

Management Comments

• Management of the Company is making efforts to raise additional funding until a registration statement relating to an equity funding facility is in effect.
• Management continues to focus its resources on the Company’s other active business segments and strategic initiatives.
• The Board approved a capital raise of up to $5 million through equity and/or convertible debt.
• This move aligns with the Company’s strategy to become a leader in AI-driven advisory services.
• We will need to raise additional funds, particularly if we are unable to generate positive cash flow as a result of our operations.
• We estimate that based on current plans and assumptions, that our available cash will be insufficient to satisfy our cash requirements under our present operating expectations.
• The inability to obtain additional capital may restrict our ability to grow and may reduce our ability to continue to conduct business operations. If we are unable to obtain additional financing, we will be required to cease our operations.
• To date, we have not considered this alternative, nor do we view it as a likely occurrence.
• Management concluded that our disclosure controls and procedures were ineffective as of August 31, 2025, because of the Company’s limited resources and limited number of employees.

Industry Context

Hestia Insight's pivot towards AI product development and IP-based consulting aligns with a broader industry trend of digital transformation and the increasing integration of artificial intelligence across various sectors, including healthcare and biotech. Many companies are seeking to leverage AI for efficiency, innovation, and competitive advantage. However, the company's current financial instability and 'going concern' warning highlight the significant challenges faced by smaller entities attempting such a pivot, especially when divesting from established (albeit unprofitable) legacy operations. The competitive landscape for AI-driven advisory services is rapidly evolving, with both established tech giants and numerous startups vying for market share.

Comparison to Industry Standards

• The significant decline in revenue from over $1.3 million to $8,000 is highly unusual and far below industry standards for a publicly traded company, indicating a near-complete cessation of prior business activities without immediate replacement revenue.
• The substantial net loss and accumulated deficit, coupled with the 'going concern' warning, place the company significantly below financial health benchmarks for most public companies, which typically aim for profitability and positive cash flow from operations.
• The ineffectiveness of disclosure controls and procedures, attributed to limited resources, is a red flag compared to robust internal control environments expected of public companies, regardless of size.
• The heavy reliance on related-party loans for financing, with a significant increase in such debt, suggests a lack of access to conventional financing, which is not standard for healthy public companies.
• The unrecorded $64,000 receivable from Aqua Medical due to liquidity concerns of the debtor indicates poor asset quality and collection issues, which is below industry best practices for managing receivables.
• While the strategic shift to AI is a positive trend, the company's current financial state and lack of immediate revenue from this new focus make it difficult to compare its operational performance to successful AI development or IP consulting firms.

Corporate Governance

Legal Proceedings

• The company is not currently a party to any material legal proceedings that would have a material adverse effect on its business, operating results, financial condition, or cash flows.
• Acknowledges that ordinary routine litigation incidental to normal business operations may occur from time to time.

Related Party Transactions

• On January 15, 2024, a $50,000 note payable was entered into with ECL Capital Partners Corp, extended until January 15, 2026, bearing 6.00% interest per annum.
• In August 2024, an additional $3,931 short-term, interest-free loan was received from Mr. Edward C. Lee.
• On August 25, 2024, a $25,000 note payable was entered into with ECL Capital Partners Corp, due August 24, 2025, bearing 6.00% interest per annum.
• On February 17, 2025, a $25,000 note payable was entered into with Mr. Edward Lee, due February 17, 2026, bearing 6.00% interest per annum.
• On March 17, 2025, a $25,000 note payable was entered into with Mr. Edward Lee, due March 17, 2026, bearing 6.00% interest per annum.
• On June 30, 2025, a $10,000 note payable was entered into with Mr. Edward Lee, due June 30, 2026, bearing 6.00% interest per annum.
• On July 31, 2025, a $12,500 note payable was entered into with Mr. Edward Lee, due July 31, 2026, bearing 6.00% interest per annum.
• On August 15, 2025, a $17,500 note payable was entered into with Mr. Li, due August 15, 2026, bearing 6.00% interest per annum.
• Total Notes Payable, related party, increased to $173,844 as of August 31, 2025, from $78,931 on November 30, 2024.

Stakeholder Impact

• Shareholders: Significant dilution risk from the planned equity/convertible debt capital raise. Existing shareholders face substantial losses due to the net loss, decreased equity, and 'going concern' uncertainty, potentially leading to a loss of entire investment.
• Employees: The company has only three employees and relies on independent contractors, suggesting a lean operation. The strategic shift and financial instability could impact job security or future hiring.
• Customers: The discontinuation of vending operations means former vending customers are no longer served. New customers for AI product development and IP-based consulting are crucial for the company's future, but current revenue is minimal.
• Suppliers/Creditors: Increased related-party debt and the 'going concern' warning indicate heightened risk for creditors, particularly non-related parties, regarding timely repayment.

Next Steps

• Raise additional funding through equity and/or convertible debt, up to $5 million.
• Expand the AI development team.
• Accelerate R&D in AI product development.
• Market AI consulting tools.
• Pursue strategic acquisitions, licensing, or joint ventures in healthcare and biotech technologies.
• Monitor the situation with the Aqua Medical receivable and recognize it if collection becomes probable.

Key Dates

Recommendation

The company is in severe financial distress, evidenced by a drastic revenue decline, substantial net loss, significant decrease in assets and equity, and an explicit 'going concern' warning from management. Disclosure controls are ineffective. While a strategic pivot to AI and a planned capital raise are mentioned, the current financial state and operational challenges present an extremely high risk profile. The reliance on related-party loans and the unrecorded receivable from Aqua Medical further highlight underlying weaknesses. Investors face a high probability of significant capital loss, making a 'strong sell' recommendation appropriate.

Keywords

Hestia Insight, 10-Q, SEC Filing, Financial Report, Q3 2025, Net Loss, Revenue Decline, AI Development, IP Consulting, Strategic Shift, Vending Operations, Going Concern, Capital Raise, Healthcare Sector, Biotech Sector, Equity Investments, Related Party Loans, Corporate Governance, Disclosure Controls